Baicalein / Casp3 Cancer Research Results

Ba, Baicalein: Click to Expand ⟱
Features:

Baicalein — Baicalein is a polyphenolic flavone aglycone found primarily in Scutellaria baicalensis and related botanicals, and is the active unconjugated counterpart of baicalin after intestinal/microbial deconjugation and re-conjugation cycling. It is formally classified as a small-molecule natural-product flavonoid with pleiotropic signaling, redox, metabolic, and enzyme-modulatory activity. Standard abbreviations include Ba or BE. In cancer literature it is best characterized as a multi-target preclinical anticancer scaffold rather than an established oncology drug, with relatively strong mechanistic support for apoptosis induction, survival-pathway suppression, anti-invasive signaling, and 12-lipoxygenase inhibition, but with major translational constraints from poor aqueous solubility, extensive first-pass glucuronidation/sulfation, transporter-enzyme interactions, and the likelihood that many in-vitro exposure levels exceed typical systemic aglycone exposure.

Primary mechanisms (ranked):

  1. 12-lipoxygenase inhibition with downstream suppression of pro-survival, pro-migratory, and pro-angiogenic lipid signaling.
  2. Intrinsic apoptosis induction via mitochondrial destabilization, cytochrome-c release, caspase-9/3 activation, and BAX:BCL-2 shift.
  3. PI3K/AKT survival-axis repression, often with PTEN restoration and reduced downstream anti-apoptotic signaling.
  4. Redox stress modulation with tumor-context ROS↑ and impaired antioxidant buffering, but normal-cell antioxidant protection in oxidative-injury models.
  5. ER-stress and Ca²⁺ stress coupling that amplifies mitochondrial commitment to cell death.
  6. Suppression of glycolysis / hypoxia adaptation, including HIF-1α, HK2, LDHA, PDK1, PKM2, and GLUT1 in relevant models.
  7. Anti-invasive / anti-metastatic signaling through MMP2/MMP9 and related migration programs.
  8. Anti-angiogenic signaling with VEGF reduction.
  9. Contextual chemo- and radiosensitization in selected models.

Bioavailability / PK relevance: Oral translation is constrained by very low water solubility and extensive intestinal/hepatic phase-II metabolism to glucuronide and sulfate conjugates. Human phase-I data show rapid absorption of tablet formulations with peak plasma levels around 2 hours, steady state after repeated dosing, and major circulating/excreted metabolite burden rather than sustained high parent-aglycone exposure. Microbiota, UGT-dependent reconjugation, and transporter/CYP interactions are clinically relevant variables. Intestinal microbiota are mechanistically relevant because baicalin is converted to baicalein before absorption. Poor translational PK is reinforced by very low aqueous solubility, reported around 16.82 μg/mL, and by formulation studies showing large exposure gains after cocrystal/nanodelivery approaches.

In-vitro vs systemic exposure relevance: Many anticancer cell studies use roughly 10–50 μM and sometimes higher. That generally exceeds typical reported average human plasma exposure for parent baicalein after oral dosing, so direct translation of higher-concentration in-vitro effects should be treated cautiously unless formulation enhancement, local delivery, tissue enrichment, conjugate deconjugation, or combination use is specifically justified.

Clinical evidence status: Strong preclinical evidence across multiple tumor models; limited animal efficacy support; human clinical experience is mainly phase-I safety/PK and non-oncology development contexts. There is no established cancer indication or mainstream regulatory oncology deployment as of March 12, 2026.

Here are some of the key pathways and mechanisms implicated in its anticancer effects:
-Apoptosis and Cell Cycle Regulation
-Reactive Oxygen Species ROS↑ Generation and Oxidative Stress (Context and dose dependent)
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, Ca+2↑, Cyt‑c↑, Casp3↑">Caspase-3↑, Caspase-9↑, DNA damage↑,
-Baicalein’s effects on ROS are context-dependent. In some cancer cells, it promotes ROS production to a degree that overwhelms the antioxidant defenses. Elevated ROS levels can damage cellular components and promote apoptosis, essentially tipping the balance toward cell death.
-Conversely, in normal cells, baicalein may exhibit antioxidant properties and reduce ROS↓ under conditions of oxidative stress, highlighting its dual role.
- May Lowers AntiOxidant defense in Cancer Cells: NRF2↓, GSH↓, HO-1↓
- Raises AntiOxidant defense in Normal Cells: NRF2↑, SOD↑, GSH↑, Catalase↑, HO-1↑,
-MAPK, ERK Pathway:
-PI3K/Akt Pathway: Inhibition of the PI3K, Akt pathway by baicalein.
-NF-κB Pathway: Baicalein can inhibit
-Inhibition of Metastasis and Invasion: Baicalein can downregulate MMPs, MMP2, MMP9
-Angiogenesis Suppression: VEGF
-Baicalein is a well-known inhibitor of 12-lipoxygenase
-inhibitor of Glycolysis↓ and HIF-1α↓, PKM2↓, cMyc↓, PDK1↓, GLUT1↓, LDHA↓, HK2↓
- promoting PTEN
-chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, neuroprotective, Cognitive, Renoprotection, Hepatoprotective, cardioProtective,
- Selectivity: Cancer Cells vs Normal Cells
-low bioavailability but liposomal may improve bioavailability

In summary, baicalein affects cancer cells by modulating multiple pathways—promoting apoptosis, causing cell cycle arrest, generating or modulating ROS levels, inhibiting survival and proliferative signaling (such as MAPK, PI3K/Akt, and NF-κB pathways), and reducing angiogenesis and metastasis.

Many animal studies, doses have been reported in the range of approximately 10 to 200 mg/kg body weight.
For example, some studies exploring anticancer or anti-inflammatory effects in rodent models have used doses around 50–100 mg/kg.
However, these doses do not directly translate to human dosages.
Some human studies or formulations (where they are used as nutraceuticals or supplements) may suggest dosing in the range of a few hundred milligrams per day of the extract, but it is often not standardized to a specific amount of baicalein or baicalin.
-mix with oil?

-ic50 cancer cells 10-30uM, normal cells 50-100uM
-Animal studies, 10 to 100 mg/kg.
-Reported to induce apoptosis, cause cell cycle arrest, inhibit angiogenesis, and modulate various signaling pathways (e.g., STAT3, NF-κB, MAPK).

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 12-Lipoxygenase axis ↓ 12-LOX, ↓ 12-HETE-linked survival / migration signaling ↔ or modest effect P, R Direct target-level antitumor leverage One of the more mechanistically specific baicalein actions. Supports anti-proliferative, anti-migratory, and anti-angiogenic behavior in susceptible tumors.
2 Mitochondria / MPTP ↓ ΔΨm, ↑ mitochondrial dysfunction, ↑ Cyt-c release ↔ or protected in oxidative-injury models R, G Intrinsic apoptosis commitment Mitochondrial collapse is a major convergence point downstream of redox, ER-stress, and survival-pathway suppression.
3 Caspase apoptosis program ↑ BAX, ↓ Bcl-2, ↑ Casp9, ↑ Casp3, ↑ apoptosis ↔ minimal activation G Cell-death execution Widely reported across tumor models; often follows mitochondrial injury rather than representing the earliest event.
4 PI3K / AKT / PTEN axis ↓ PI3K, ↓ p-AKT, ↑ PTEN ↔ or context-dependent R, G Survival suppression A central non-redox pathway that helps explain apoptosis sensitization, cell-cycle arrest, and metabolic downshift.
5 ROS balance ↑ ROS (dose-dependent) or ROS⇅ depending on model ↓ ROS under oxidative challenge P, R, G Tumor-selective redox stress Dual behavior is important: pro-oxidant pressure is common in malignant cells, whereas antioxidant cytoprotection is well documented in stressed non-malignant cells.
6 NRF2 / HO-1 / GSH antioxidant buffering ↓ NRF2, ↓ HO-1, ↓ GSH (context-dependent) ↑ NRF2, ↑ HO-1, ↑ GSH, ↑ SOD / catalase R, G Selectivity gate This divergent redox-buffer response likely contributes to cancer-versus-normal selectivity, but it is model-dependent and should not be overstated as universal.
7 ER stress and Ca²⁺ stress coupling ↑ ER stress, ↑ CHOP, ↑ UPR, ↑ Ca²⁺ dysregulation ↔ buffered homeostasis R, G Stress amplification Likely helps transmit redox/survival perturbation into irreversible mitochondrial death signaling.
8 Glycolysis / HIF-1α adaptation ↓ HIF-1α, ↓ HK2, ↓ LDHA, ↓ PDK1, ↓ PKM2, ↓ GLUT1, ↓ glycolysis ↔ G Metabolic constraint Most convincing in hypoxia-adaptation and gastric / radioresistance models. Usually reflects later transcriptional or adaptation-level effects.
9 NF-κB and MAPK / ERK signaling ↓ NF-κB, MAPK / ERK modulation (often ↓ ERK tone) ↔ or context-dependent P, R, G Signal reprogramming Supports lower inflammatory-survival tone, apoptosis sensitization, and reduced proliferation, but exact direction within MAPK branches can vary by tumor model.
10 Invasion / metastasis axis ↓ MMP2, ↓ MMP9, ↓ migration / invasion ↔ G Anti-invasive phenotype Phenotypically important and relatively consistent, though usually secondary to broader signaling reprogramming.
11 Angiogenesis axis ↓ VEGF, ↓ microvessel support ↔ G Anti-angiogenic support Supported by xenograft and lung-cancer data; best viewed as an adjunct downstream effect rather than sole primary mechanism.
12 Radiosensitization / chemosensitization ↑ treatment sensitivity (context-dependent) Potential normal-tissue protection in oxidative-injury contexts G Combination-use leverage Mechanistically plausible via HIF-1α/glycolysis suppression, NF-κB restraint, and apoptosis priming, but still preclinical and heterogeneous.
13 Clinical Translation Constraint Low parent exposure, variable microbiota handling, rapid conjugation, likely concentration gap May favor safety but complicates efficacy extrapolation G Delivery limitation Poor solubility, strong first-pass metabolism, conjugate predominance, possible CYP/transporter interactions, and lack of oncology-grade clinical validation are the main barriers.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/physical–chemical effects; direct enzymatic or rapid signaling shifts)
  • R: 30 min–3 hr (redox signaling and acute stress-response signaling)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
2627- Ba,  Cisplatin,    Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways
RenoP↑, *iNOS↑, *TNF-α↓, *IL6↓, *NF-kB↓, *MAPK↓, *ERK↓, *JNK↓, *antiOx↑, *NRF2↓, *HO-1↑, *Cyt‑c∅, *Casp3∅, *Casp9∅, *PARP∅,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Functional Outcomes ⓘ

RenoP↑, 1,  
Total Targets: 1

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   HO-1↑, 1,   NRF2↓, 1,  

Cell Death ⓘ

Casp3∅, 1,   Casp9∅, 1,   Cyt‑c∅, 1,   iNOS↑, 1,   JNK↓, 1,   MAPK↓, 1,  

DNA Damage & Repair ⓘ

PARP∅, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL6↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  
Total Targets: 15

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:38  Target#:42  State#:%  Dir#:6
  wNotes=0  sortOrder:rid,rpid

 

Home Page